000181272 001__ 181272
000181272 005__ 20240229145644.0
000181272 0247_ $$2doi$$a10.1038/s41598-022-14977-2
000181272 0247_ $$2pmid$$apmid:35982066
000181272 0247_ $$2altmetric$$aaltmetric:134700267
000181272 037__ $$aDKFZ-2022-01915
000181272 041__ $$aEnglish
000181272 082__ $$a600
000181272 1001_ $$aRautajoki, Kirsi J$$b0
000181272 245__ $$aPTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
000181272 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2022
000181272 3367_ $$2DRIVER$$aarticle
000181272 3367_ $$2DataCite$$aOutput Types/Journal article
000181272 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660915800_8349
000181272 3367_ $$2BibTeX$$aARTICLE
000181272 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181272 3367_ $$00$$2EndNote$$aJournal Article
000181272 520__ $$aOligodendrogliomas are typically associated with the most favorable prognosis among diffuse gliomas. However, many of the tumors progress, eventually leading to patient death. To characterize the changes associated with oligodendroglioma recurrence and progression, we analyzed two recurrent oligodendroglioma tumors upon diagnosis and after tumor relapse based on whole-genome and RNA sequencing. Relapsed tumors were diagnosed as glioblastomas with an oligodendroglioma component before the World Health Organization classification update in 2016. Both patients died within 12 months after relapse. One patient carried an inactivating POLE mutation leading to a clearly hypermutated progressed tumor. Strikingly, both relapsed tumors carried focal chromosomal rearrangements in PTPRD and CNTNAP2 genes with associated decreased gene expression. TP53 mutation was also detected in both patients after tumor relapse. In The Cancer Genome Atlas (TCGA) diffuse glioma cohort, PTPRD and CNTNAP2 expression decreased by tumor grade in oligodendrogliomas and PTPRD expression also in IDH-mutant astrocytomas. Low expression of the genes was associated with poor overall survival. Our analysis provides information about aggressive oligodendrogliomas with worse prognosis and suggests that PTPRD and CNTNAP2 expression could represent an informative marker for their stratification.
000181272 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000181272 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181272 7001_ $$aJaatinen, Serafiina$$b1
000181272 7001_ $$aTiihonen, Aliisa M$$b2
000181272 7001_ $$aAnnala, Matti$$b3
000181272 7001_ $$aVuorinen, Elisa M$$b4
000181272 7001_ $$aKivinen, Anni$$b5
000181272 7001_ $$aRauhala, Minna J$$b6
000181272 7001_ $$0P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7$$aMaass, Kendra$$b7$$udkfz
000181272 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b8$$udkfz
000181272 7001_ $$aYli-Harja, Olli$$b9
000181272 7001_ $$aHelén, Pauli$$b10
000181272 7001_ $$aHaapasalo, Joonas$$b11
000181272 7001_ $$aHaapasalo, Hannu$$b12
000181272 7001_ $$aZhang, Wei$$b13
000181272 7001_ $$aNykter, Matti$$b14
000181272 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-022-14977-2$$gVol. 12, no. 1, p. 14083$$n1$$p14083$$tScientific reports$$v12$$x2045-2322$$y2022
000181272 909CO $$ooai:inrepo02.dkfz.de:181272$$pVDB
000181272 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000181272 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000181272 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000181272 9141_ $$y2022
000181272 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000181272 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-08T09:38:07Z
000181272 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-08T09:38:07Z
000181272 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-08-08T09:38:07Z
000181272 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2022-11-09
000181272 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2022-11-09
000181272 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000181272 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000181272 980__ $$ajournal
000181272 980__ $$aVDB
000181272 980__ $$aI:(DE-He78)B062-20160331
000181272 980__ $$aI:(DE-He78)HD01-20160331
000181272 980__ $$aUNRESTRICTED